vs
Side-by-side financial comparison of FENNEC PHARMACEUTICALS INC. (FENC) and Marygold Companies, Inc. (MGLD). Click either name above to swap in a different company.
FENNEC PHARMACEUTICALS INC. is the larger business by last-quarter revenue ($13.8M vs $7.6M, roughly 1.8× Marygold Companies, Inc.). Marygold Companies, Inc. runs the higher net margin — -7.5% vs -34.7%, a 27.2% gap on every dollar of revenue. On growth, FENNEC PHARMACEUTICALS INC. posted the faster year-over-year revenue change (73.8% vs -4.5%). Over the past eight quarters, Marygold Companies, Inc.'s revenue compounded faster (-1.5% CAGR vs -26.3%).
Fennec Pharmaceuticals Inc. is a biopharmaceutical firm focused on developing and commercializing therapies to reduce treatment-related side effects in pediatric cancer patients. Its lead product targets chemotherapy-induced ototoxicity, with core North American markets serving oncology providers and vulnerable pediatric patient groups.
Marygold Companies, Inc. is a U.S.-headquartered diversified holding company that operates across three core segments: financial services, specialty manufacturing, and consumer goods. It primarily caters to North American markets, driving long-term value growth via strategic investment in, and operational optimization of, its portfolio of subsidiary entities.
FENC vs MGLD — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $13.8M | $7.6M |
| Net Profit | $-4.8M | $-576.0K |
| Gross Margin | — | 74.0% |
| Operating Margin | -18.5% | -8.3% |
| Net Margin | -34.7% | -7.5% |
| Revenue YoY | 73.8% | -4.5% |
| Net Profit YoY | -141.1% | 67.0% |
| EPS (diluted) | $-0.17 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.8M | $7.6M | ||
| Q3 25 | $12.5M | $7.0M | ||
| Q2 25 | $9.7M | $7.2M | ||
| Q1 25 | $8.8M | $7.0M | ||
| Q4 24 | $7.9M | $8.0M | ||
| Q3 24 | $7.0M | $7.9M | ||
| Q2 24 | $7.3M | $8.3M | ||
| Q1 24 | $25.4M | $7.9M |
| Q4 25 | $-4.8M | $-576.0K | ||
| Q3 25 | $-638.0K | $-356.0K | ||
| Q2 25 | $-3.2M | $-1.5M | ||
| Q1 25 | $-1.2M | $-1.0M | ||
| Q4 24 | $-2.0M | $-1.7M | ||
| Q3 24 | $-5.7M | $-1.6M | ||
| Q2 24 | $-5.6M | $-1.9M | ||
| Q1 24 | $12.8M | $-529.0K |
| Q4 25 | — | 74.0% | ||
| Q3 25 | — | 77.0% | ||
| Q2 25 | — | 67.8% | ||
| Q1 25 | — | 75.0% | ||
| Q4 24 | — | 74.1% | ||
| Q3 24 | — | 73.1% | ||
| Q2 24 | — | 72.5% | ||
| Q1 24 | — | 70.5% |
| Q4 25 | -18.5% | -8.3% | ||
| Q3 25 | -1.5% | -18.2% | ||
| Q2 25 | -28.3% | -16.5% | ||
| Q1 25 | -9.2% | -21.4% | ||
| Q4 24 | -11.8% | -22.8% | ||
| Q3 24 | -74.6% | -27.4% | ||
| Q2 24 | -69.4% | -33.3% | ||
| Q1 24 | 54.2% | -18.7% |
| Q4 25 | -34.7% | -7.5% | ||
| Q3 25 | -5.1% | -5.1% | ||
| Q2 25 | -32.7% | -20.4% | ||
| Q1 25 | -13.3% | -14.4% | ||
| Q4 24 | -25.0% | -21.8% | ||
| Q3 24 | -82.2% | -20.1% | ||
| Q2 24 | -76.5% | -22.5% | ||
| Q1 24 | 50.6% | -6.7% |
| Q4 25 | $-0.17 | $-0.01 | ||
| Q3 25 | $-0.02 | $-0.01 | ||
| Q2 25 | $-0.11 | $-0.04 | ||
| Q1 25 | $-0.04 | $-0.02 | ||
| Q4 24 | $-0.02 | $-0.04 | ||
| Q3 24 | $-0.21 | $-0.04 | ||
| Q2 24 | $-0.20 | $-0.05 | ||
| Q1 24 | $0.41 | $-0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $36.8M | $11.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $35.5M | $22.7M |
| Total Assets | $70.6M | $27.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $36.8M | $11.6M | ||
| Q3 25 | $21.9M | $12.5M | ||
| Q2 25 | $18.7M | $12.8M | ||
| Q1 25 | $22.7M | $15.6M | ||
| Q4 24 | $26.6M | $14.9M | ||
| Q3 24 | $40.3M | $17.5M | ||
| Q2 24 | $43.1M | $15.0M | ||
| Q1 24 | $51.2M | $16.1M |
| Q4 25 | — | — | ||
| Q3 25 | $19.4M | — | ||
| Q2 25 | $19.4M | — | ||
| Q1 25 | $19.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | $32.1M | — | ||
| Q2 24 | $31.8M | — | ||
| Q1 24 | $31.3M | — |
| Q4 25 | $35.5M | $22.7M | ||
| Q3 25 | $-4.5M | $22.9M | ||
| Q2 25 | $-7.5M | $23.0M | ||
| Q1 25 | $-5.9M | $24.3M | ||
| Q4 24 | $-5.9M | $23.4M | ||
| Q3 24 | $-5.2M | $25.5M | ||
| Q2 24 | $-1.4M | $26.6M | ||
| Q1 24 | $3.0M | $28.4M |
| Q4 25 | $70.6M | $27.8M | ||
| Q3 25 | $49.3M | $28.4M | ||
| Q2 25 | $44.9M | $30.4M | ||
| Q1 25 | $46.4M | $33.5M | ||
| Q4 24 | $44.9M | $33.0M | ||
| Q3 24 | $58.9M | $35.9M | ||
| Q2 24 | $63.2M | $32.9M | ||
| Q1 24 | $69.2M | $33.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 10.40× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.0M | $-908.0K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.0M | $-908.0K | ||
| Q3 25 | $1.5M | $-533.0K | ||
| Q2 25 | $-3.7M | $-3.3M | ||
| Q1 25 | $-4.3M | $-1.2M | ||
| Q4 24 | $-1.5M | $-770.0K | ||
| Q3 24 | $-2.2M | $-893.0K | ||
| Q2 24 | $-8.4M | $-1.9M | ||
| Q1 24 | $39.0M | $-658.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | $-562.0K | ||
| Q2 25 | — | $-3.4M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-776.0K | ||
| Q3 24 | — | $-940.0K | ||
| Q2 24 | — | $-2.0M | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -8.1% | ||
| Q2 25 | — | -46.8% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -9.7% | ||
| Q3 24 | — | -11.9% | ||
| Q2 24 | — | -23.8% | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.4% | ||
| Q2 25 | — | 0.7% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | — | 0.7% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 3.04× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FENC
Segment breakdown not available.
MGLD
| Fund Management Related Party | $4.6M | 60% |
| Food Products | $1.7M | 22% |
| Beauty Products | $1.2M | 15% |
| Other | $268.0K | 4% |
